Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.31 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.31 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215327 | 0.87 | PDCD1 (0.35) | CYP3A4SMYD2KDM4EHTTSMN1; SMN2 | |
| SCHEMBL3692210 | 0.85 | — | — | |
| SCHEMBL5872822 | 0.84 | MRGPRX4 (0.34) | MRGPRX4CYP3A4SMYD2HTTSMN1; SMN2 | |
| SCHEMBL2213824 | 0.81 | SMYD2 (0.31) | CYP3A4SMYD2HTTSMN1; SMN2 | |
| SCHEMBL1564661 | 0.80 | HTT (0.44) | MRGPRX4HTTALDH1A1 | |
| SCHEMBL2306627 | 0.78 | MAOB (0.33) | SMYD2ALDH1A1HPGDKMT2A | |
| SCHEMBL2214318 | 0.77 | SMYD2 (0.32) | CYP3A4SMYD2HTTSMN1; SMN2 | |
| SCHEMBL34474697 | 0.77 | MAPT (0.44) | MRGPRX4CYP3A4SMYD2KDM4EHTT | |
| SCHEMBL31725394 | 0.75 | FOLH1 (0.37) | ALDH1A1 | |
| SCHEMBL5014338 | 0.74 | KDM4E (0.36) | SMYD2KDM4ESMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178064-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | ASTRAZENECA R&D (SE) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178064-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | TBCA, TUBA1A, BROX | MRGPRX4 3592/4885CYP3A4 1295/4885SMYD2 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.